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RESEARCH PAPER
Indirect costs of adult pneumococcal disease and the productivity-based rate of
return to the 13-valent pneumococcal conjugate vaccine for adults in Turkey
J. P. Sevilla a, Andrew Stawasz a*, Daria Burnesa, Anubhav Agarwala#, Basak Hacibedelb, Kerem Helvacioglub,
Reiko Satoc, and David E. Blooma
aLife Sciences Group, Data for Decisions, LLC, Waltham, MA, USA; bHealth Economics and Outcomes Research, Pfizer Turkey, Istanbul, Turkey;
cHealth Economics and Outcomes Research, Pfizer Inc, Collegeville, PA, USA
ABSTRACT
Productivity benefits of health technologies are ignored in typical economic evaluations from
a health payer’s perspective, risking undervaluation. We conduct a productivity-based cost-benefit
analysis from a societal perspective and estimate indirect costs of adult pneumococcal disease,
vaccination benefits from the adult 13-valent pneumococcal conjugate vaccine (PCV13 Adult), and
rates of return to PCV13 Adult for a range of hypothetical vaccination costs. Our context is Turkey’s
funding PCV13 for the elderly and for non-elderly adults with select comorbidities within the
Ministry of Health’s National Immunization Program. We use a Markov model with one-year cycles.
Indirect costs from death or disability equal the expected present discounted value of lifetime losses
in the infected individual’s paid and unpaid work and in caregivers’ paid work. Vaccination benefits
comprise averted indirect costs. Rates of return equal vaccination benefits divided by vaccination
costs, minus one. Input parameters are from public data sources. We model comorbidities’ effects by
scalar multiplication of the parameters of the general population. Indirect costs per treatment
episode of inpatient community-acquired pneumonia (CAP), bacteremia, and meningitis – but not
for outpatient CAP – approach or exceed Turkish per capita gross domestic product. Vaccination
benefits equal $207.02 per vaccination in 2017 US dollars. The rate of return is positive for all
hypothetical costs below this. Results are sensitive to herd effects from pediatric vaccination and
vaccine efficacy rates. For a wide range of hypothetical vaccination costs, the rate of return
compares favorably with those of other global development interventions with well-established
strong investment cases.
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Vaccination is among the most impactful public health inter-
ventions of our age.1 However, innovation has multiplied the
number of health technologies competing for reimbursement
from a health payer’s (henceforth “payer”) budget. Payers and
finance ministries therefore increasingly scrutinize vaccines’
and other technologies’ value for money. Lively debate centers
on the scope of value and the proper analytical framework for
quantifying that value.2-4 We contribute to this debate by
addressing productivity’s role in value assessments in the
context of vaccinating Turkish adults with the 13-valent pneu-
mococcal conjugate vaccine (PCV13).
1.1. Choice of perspective and analysis
Two specification choices are central to value-for-money cal-
culations. First is the relevant perspective, where the most
common and important choices are the health payer’s and
societal perspectives. According to the health payer’s perspec-
tive, the core elements of value are health gains–typically
denominated in quality-adjusted life years (QALYs) and
valued at the payer’s willingness-to-pay (WTP) per QALY–
and savings to the payer’s budget (typically averted direct
medical costs). According to the societal perspective, health
gains should be valued at individuals’ WTP, and the broader
socio-economic benefits of those health gains such as eco-
nomic productivity matter as well. (QALYs can in theory
reflect the productivity effects of health but in practice fail
to systematically do so.2,5-7)
The second choice is whether, within the societal perspective,
the broader socio-economic benefits of health should be quanti-
fied using cost-utility analysis (CUA) or cost-benefit analysis
(CBA). CUA assumes a constant willingness-to-pay (WTP) per
QALY regardless of, say, differential productivity consequences
across QALYs (an aspect of the so-called “a QALY is a QALY is
a QALY” assumption).4 CBA allows different units of health to
have different values, reflecting among other things their differ-
ential productivity impacts. Thus, QALYs are typically not
meaningful in CBA, and health improvements that are equiva-
lent QALY gains in CUA may have different and typically age-
varying values within CBA.
CONTACT J. P. Sevilla jsevilla@gmail.com Data for Decisions, LLC, 681 Main Street, Suite 3-37, Waltham, MA 02451, USA
*Present address: Harvard Law School, Cambridge, MA, USA
#Present address: University of Ottawa, Ottawa, ON, Canada
Supplemental data for this article can be accessed online at http://dx.doi.org/10.1080/21645515.2019.1708668.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
2020, VOL. 16, NO. 8, 1923–1936
https://doi.org/10.1080/21645515.2019.1708668
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1.2. Productivity
An important category of value within the societal perspective
is productivity because it enables consumption, which along
with leisure are the two direct sources of utility within stan-
dard economics. The value of health is at least as large as that
of its productivity effects since there’s more to life than con-
sumption. Thus, productivity benefits are a lower bound
measure of individuals’ WTP for health.
A first issue here is whether to adopt the human capital
approach (which counts lifetime productivity losses to the
individual from mortality and morbidity) or the friction
approach (which counts only aggregate market production
losses, which can be mitigated by replacing sick or deceased
workers). We adopt the human capital approach for the
following reasons. First, the societal perspective is of policy
interest in part because it encompasses (among many per-
spectives) the perspective of the vaccinated individual. The
vaccinated individual is indifferent to replacement, so the
productivity that reflects the vaccinated individual’s WTP
for health is given by the human capital rather than the
friction cost approach. Second, the Second Panel recommends
the human capital approach.2 It argues that even in develop-
ing countries with high unemployment, the formally unem-
ployed are likely to be productive in informal labor markets
and unpaid work, causing friction cost analyses to understate
productivity losses from replacing disabled or deceased work-
ers. Third, in our analysis we adjust paid work by employ-
ment rates to reflect the impact of high unemployment.
Traditional productivity analysis relies on market transac-
tions to reveal value and so focuses on paid work. But
unpaid work produces valuable consumable goods and ser-
vices that contribute to utility so ignoring it produces down-
ward-biased estimates of well-being, disease burdens, and
vaccination benefits. Omitting unpaid work inequitably
undervalues the contributions of women and the elderly,
whose work is more likely to be unpaid than that of work-
ing-age men.8 Such omission underappreciates the harm
(including to children, the sick, and the elderly) and the
financial and economic costs (from having to pay a helper
or impose time burdens on friends and family) that come
from a loss of unpaid production. Unpaid work has grown
in importance in economic research,9 Systems of National
Accounts,10 economic evaluation reference cases,2 and well-
being measurement.11
1.3. Pneumococcal vaccination policy in Turkey
Two pneumococcal vaccines exist for adults. The 23-valent
pneumococcal polysaccharide vaccine (PPV23) is effective
against invasive pneumococcal disease (IPD), but has ques-
tionable effectiveness against community-acquired pneumo-
nia (CAP).12 PCV13 is effective against both: its efficacy
against IPD as well as CAP was first demonstrated in
a randomized controlled trial conducted in Dutch elderly.13
In Turkey, the Ministry of Health (MoH), in consultation
with the Advisory Board of Immunization (ABI), decides
whether to recommend vaccines for reimbursement as part
of the National Immunization Program. PCV13 was first
approved in Europe in 2009,14 and the ABI has recommended
pneumococcal vaccines in children since 2008.15 PPV23 has
been recommended and reimbursed for at-risk and elderly
adults since 2007.16 In 2016, the ABI and MoH approved
a comprehensive adult immunization program, as part of
which PCV13 is now recommended and reimbursed for all
adults aged 65 years and older, as well as for adults aged
18–64 years with certain comorbid diseases.17 Our analysis
sheds light on the value for money of Turkey’s adding PCV13
Adult reimbursement to the pre-2016 status quo of adult
PPV23 reimbursement.
1.4. Literature on economic evaluation of PCV13 adult
The literature on the economic evaluation of PCV13 Adult
typically adopts the health payer’s perspective,18 uses CUA,
ignores indirect costs, and where indirect costs are considered
uses the friction approach and ignores unpaid work.
Dirmesropian et al. (2015)19 review pre-2015 studies
a majority of which found PCV13 adult to be cost-effective
but all of which were hampered by not having access to the
important CAPITA trial estimates of vaccine efficacy. A more
recent review by Treskova et al. (2019)18 stratifies the newer
literature according to assumptions about herd effects from
pediatric vaccination (i.e., whether effects were ongoing or
completed, whether effects were from pediatric PCV13
(PCV13 Pediatric) or from pediatric 10-valent pneumococcal
conjugate vaccine (PCV10 Pediatric), or whether there was
a switch in pediatric vaccination from PCV10 to PCV13 or
vice versa), and according to the policy being evaluated
(PPV23 versus no vaccination, PCV13 versus no vaccination,
and adding PCV13 to PPV23). Of the four studies that eval-
uate the addition of PCV13 Adult to adult PPV23 (as was the
case in Turkey), van Hoek and Miller (2016),20 Blommaert
et al. (2016),21 and Willem et al. (2018)22 found doing so to be
cost-ineffective, while Stoecker et al. (2016)23 found it to be
cost-effective only in the short run before herd effects fully set
in. Treskova et al. (2019)18 conclude from this evidence that
PCV13 Adult is not cost-effective in the presence of herd
effects from PCV13 Pediatric.
Economic evaluation of adult pneumococcal vaccination in
Turkey exists, but these either focus on adult PPV2316 or
focus on PCV but do so from a health payer’s perspective
and without the benefit of CAPITA vaccine efficacy
estimates.24,25 Two evaluations of PCV13 Adult consider pro-
ductivity losses: Mangen et al.(2015)26 and Heo et al. (2017).27
Both ignore unpaid work, the former uses friction costs to
estimate the productivity losses from mortality, and the latter
does not consider productivity losses from mortality.
2. Methods and data
This section describes our methods and data. TheMethodological
Appendix provides details.
2.1. Objectives
We conduct a productivity-based CBA from a societal per-
spective. Our societal perspective reflects multiple interests,
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including those of the individual, household, employer,
public sector, and larger society. Our societal perspective
is a limited rather than full version because we include only
productivity benefits and ignore the intrinsic value of
health (this is the value captured by QALYs in CUA), direct
costs, and non-health-sector benefits other than productiv-
ity. Though direct costs are typically included in economic
evaluations, we omit them to focus on the importance of
indirect costs to vaccine evaluation and to assess whether
PCV13 represents strong value-for-money on indirect cost
grounds alone.
Our CBA allows for age-varying productivity benefits
across Turkish adults of all ages. We take productivity
gains to be a lower-bound measure of patient- and societal
WTP for health gains. For reasons given above, we adopt
a human capital approach to productivity loss and incorpo-
rate three central categories of unpaid work: housework,
caregiving, and volunteering.28 Indirect costs from disease
equal the loss in expected present discounted value of life-
time pre-tax paid work and unpaid work from disease.
Vaccination benefits consist of averted indirect costs from
vaccination.
We calculate (i) the per treatment episode indirect
costs of adult pneumococcal disease (PD), (ii) the per
person vaccination benefits from PCV13 Adult, and (iii)
hypothetical rates of return to PCV13 Adult for a range
of hypothetical vaccination costs. We perform these cal-
culations in the context of Turkey’s funding PCV13 for
both all elderly adults in the general population (aged 65
and up, hereafter the “elderly subpopulation”) and non-
elderly adults with select comorbidities (aged 18–64, here-
after the “comorbid subpopulation;” we refer to the
elderly and comorbid subpopulations combined as the
“program population”) within the Ministry of Health’s
National Immunization Program. The comorbid subpopu-
lation is limited to those with the following six comor-
bidities: chronic obstructive pulmonary disease, asthma,
diabetes, chronic kidney failure, chronic heart disease,
and cancer.17
2.2. Approach to calculating societal WTP for PCV13
Different elements of how we define productivity are relevant
to different interests, as the following sections describe.
2.2.1. Vaccinated individual
For the vaccinated individual, assuming that no income trans-
fers occur between individuals, lifetime post-tax earnings,
along with nonmarket production, constrain how much mar-
ket and nonmarket goods and services the individual can
consume. Such consumption is itself a lower-bound measure
of lifetime wellbeing because other factors, such as leisure,
also contribute to wellbeing.29,30
2.2.2. Transfer beneficiaries
Whatever an individual earns or produces but does not con-
sume can be shared with others, such as household members
and friends (the individual’s “transfer beneficiaries”). The
individual’s lifetime post-tax earnings and nonmarket produc-
tivity therefore capture not only the vaccinated individual’s
wellbeing, but also that of his or her transfer beneficiaries.
2.2.3. Employers
Disabled individuals or, in the case of employees with sick
leave, employers, bear productivity losses during periods of
temporary disability.
2.2.4. Fiscal authorities
We value paid work at pre-tax earnings to partially capture
fiscal losses from disease.
2.3. Model structure
We use an age-differentiated single-cohort Markov model of
disease with one-year cycles (Figure 1).31
An uninfected cohort faces a one-time decision to vaccinate,
represented by the square node. Depending on the decision, the
cohort enters the annual Markov cycle tree at node “M.” It
subsequently faces sequential risks of non-PD-related death,
infection with one of four PD manifestations (inpatient CAP,
Figure 1. Markov model diagram. Abbreviations: B = bacteremia; ICAP = inpatient community-acquired pneumonia; M = meningitis; MD = moderate disability; OCAP =
outpatient community-acquired pneumonia; PCV13Adult = 13-valent pneumococcal conjugate vaccine for adults; PD=pneumococcal disease; PVS=persistent vegetative state;
SD = severe disability; TD = temporary disability.
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outpatient CAP, bacteremia, and meningitis), and these infec-
tions’ associated outcomes (death and various disabilities). Each
PD-related Markov state (i.e., states other than the uninfected
and non-PD death states) is a manifestation-specific outcome
and has a state utility equal to the indirect costs associated with
that outcome. Absorbing states terminate in left-pointed trian-
gles. We label nodes with capitalized letters A–E for ease of
reference (for example, all nodes labeled “A” have the same
structure and can be referred to using the same label). Indirect
costs of each state equal the loss in expected present-discounted
value of lifetime pre-tax paid work and unpaid work associated
with that state. The uninfected state and death from non-PD-
related causes do not involve PD-related costs and thus have zero
state utility. All other states involve PD-related costs and so have
positive state utility.
Vaccination produces benefits by reducing risks of con-
tracting PD (see node B in Figure 1) and therefore risks of
transitioning to states with positive state utilities. The benefit
of vaccination is the difference in expected discounted lifetime
costs (or expected discounted cumulative state utilities)
between vaccinated and unvaccinated cohorts. The policy
comparison of our evaluation is therefore one actually faced
by the Turkish Ministry of Health: “PCV13 program versus
no PCV13 program,” where we assume the impact of the
existing reimbursement of PPV23 to be constant between
the two alternatives and reflected in the incidence rates of
the “no PCV13 program” arm.
2.4. Demographic structure and temporal horizon
We apply the Markov model to a single cohort consisting of
the program population in the program’s first year, thus
measuring the benefit to vaccination in that year. This pro-
gram population consists of two subpopulations: the elderly
and comorbid subpopulations. The members of our single
cohort are differentiated by (and therefore have transition
probabilities and state utilities differentiated by) age and
comorbidity status (i.e., a binary indicator for whether or
not an individual has at least one comorbidity). We do not
disaggregate cohort members or results by gender. Evidence
from Sweden suggests that the elderly perform well on instru-
mental activities of daily living (ADLs) until age 84 and show
little impairment with respect to personal ADLs until age 90.32
This suggests that age 85 may be a threshold beyond which
functional disability will impair the ability to perform unpaid
work. This consideration, along with data scarcity for ages
after 85, lead us to conservatively assume that no individual
survives longer than 85 years of age. The longest any cohort-
member stays in the model is 68 years (i.e., an 18-year-old
who lives to age 85). Our analysis covers the calendar years
2015–2082.
2.5. Background mortality
We derive probabilities of non-PD-related death during
a cycle (see node A in Figure 1) from Eurostat life tables for
Turkey, and adjust them to control for PD-related mortality
(see the Methodological Appendix for details).33
2.6. Incidence
We assume adult vaccination does not reduce the severity of
infection.34 Lack of reliable estimates also leads us to assume no
serotype replacement or herd effects from adult vaccination.
These assumptions limit the impact of adult vaccination to
reducing PCV13-serotype (vaccine-type PD) incidence (as
opposed to also reducing the probability of severe sequelae like
death), and imply that we can limit our attention to vaccine-type
(as opposed to all-type) incidence and vaccine efficacy.
Ourmodel allows at most one treatment episode (i.e., inpatient
or outpatient medical visit) per individual per cycle. In an unvac-
cinated cohort, we set the probabilities of developing the various
manifestations of PD equal to the relevant incidence rates (i.e., the
number of infections per 100,000 person years). Thus, we impli-
citly assume only one treatment episode per infection, which is
conservative since infections may involve multiple treatments.
We use Turkey-specific 2017 Global Burden of Disease
(GBD) estimates of lower respiratory infection (LRI)
incidence,35 global population attributable fractions of LRI
due to pneumococcal pneumonia,36 a 19.4% hospitalization
rate,16 and 68% PCV13 vaccine-type coverage to derive vac-
cine-type inpatient and outpatient CAP incidence rates.37 We
use Turkey-specific 2017 GBD35 estimates of pneumococcal
meningitis incidence and 2016 European Centre for Disease
Prevention and Control (ECDC)38 data on IPD cases and
deaths for six comparator countries (Czech Republic,
Greece, Hungary, Poland, Slovakia, and Slovenia) disaggre-
gated by clinical presentation, along with a 68% PCV13 vac-
cine-type coverage rate, to derive vaccine-type bacteremia and
meningitis incidence. These comparator countries were cho-
sen based on the following criteria: (i) they have 2016 ECDC
data on both the number of IPD cases and number of IPD
deaths; (ii) they are in geographically close proximity to
Turkey (i.e., in or adjacent to Central Europe or Eastern
Europe); (iii) the per capita GDP (denominated in 2016 inter-
national dollars) is close to, or slightly higher than, Turkey’s;
and (iv) the Socio-Demographic Index (SDI)39 is equal to, or
slightly higher than, Turkey’s. See the Methodological
Appendix for more details on incidence rate construction.
2.7. Herd effects from pediatric vaccination
We assume that herd effects from Turkey’s national pediatric
PCV13 vaccination program will reduce steady state PCV13-
type incidence rates among adults by the same 88% reduction
observed in seven-valent pneumococcal conjugate vaccine
(PCV7) type incidence rates in Denmark and in the United
Kingdom after the introduction of PCV7.40,41 We also assume
that part of the transition to the steady state has already
occurred by 2015 (our model’s base year) and that the
remainder of the transition will occur from 2016 to 2019
(see the Methodological Appendix for details).
2.8. Vaccine efficacy
We derive vaccine efficacy from the Community-Acquired
Pneumonia Immunization Trial in Adults (CAPITA)
study.13 We let baseline vaccine efficacy (i.e., initial vaccine
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efficacy, before waning) decline with age among those aged 50
and up in order to account for immunosenescence following
the van Werkhoven et al. (2014)42 Cox-proportional hazard-
based analysis of CAPITA study results. This analysis implies
baseline vaccine-type efficacies against inpatient and outpati-
ent CAP of 0.80 at age 50 and 0.27 at age 85. The correspond-
ing figures for bacteremia and meningitis are 0.95 and 0.58,
respectively. We assume constant proportional decline at
intermediate ages. Since van Werkhoven et al. (2014)42 do
not provide vaccine efficacies for ages younger than 50, we
follow Mangen et al. (2015)26 in assigning the baseline vaccine
efficacy for 50-year-olds to individuals aged 18–49. This is
conservative in light of the van Werkhoven et al. (2014)42
finding that PCV13 vaccine efficacy declines with age, and the
general phenomenon of immune response declining with age.
We allow vaccine efficacy to wane over time. Consistent
with previous economic modeling of PCV13 Adult,21 we
assume that vaccine efficacy is constant for the five years
immediately following vaccination, declines 5% annually for
the next five years, then declines 10% annually for the next
five years, and falls to zero thereafter.
We call the vaccine efficacies resulting from the above
assumptions our base-case vaccine efficacies.
2.9. Case fatality and disability rates
Case fatality and disability rates determine the various transi-
tion probabilities at nodes C, D, and E in Figure 1.
We assume inpatient and outpatient CAP case fatality rates
(CFRs) of 9.2% and 0%, respectively.43 We derive bacteremia and
meningitis CFRs using 2016 data from the ECDC Surveillance
Atlas of Infectious Diseases for the above-mentioned six compara-
tor countries.38 See the Methodological Appendix for further
details.
We calculate the probability of temporary disability from
inpatient CAP and bacteremia as one minus their respective
CFRs. For meningitis, we assume five outcomes: death, per-
sistent vegetative state (PVS), severe disability, moderate dis-
ability, and temporary disability. We derive probabilities of
meningitis-related PVS, severe disability, and moderate dis-
ability from 1999–2002 data from van de Beek et al. (2004),44
with the residual probability representing the probability of
temporary disability.
2.10. Indirect costs (productivity losses)
Indirect costs constitute the state utilities associated with the
various PD-related Markov states in Figure 1. Categories of
productivity loss include lost paid work and unpaid work in
the form of housework, caregiving, and volunteering. The work
may be that of the infected individual or of the infected indivi-
dual’s formal and informal caregivers. The value of lost work
equals time lost multiplied by the value per unit of time. We
value paid work at the average pre-tax wage across all occupa-
tions (“average wage”), adjusted for the probability of employ-
ment. We value the infected individual’s unpaid work at its
replacement cost (i.e., the cost of hiring someone to do the
work) rather than at its opportunity cost (i.e., foregone
earnings),45 the former of which we estimate using the average
pre-tax wage in the elementary occupations (“unskilled wage”).
We value time spent by the infected individual’s caregivers at its
opportunity cost equal to foregone paid work. We assume the
infected individual’s social circle is nationally representative, and
that everyone in this circle is equally willing and able to miss
work to provide care, and so value this foregone paid work at the
average wage across all adults.
PD-related death, meningitis-related PVS, and severe disabil-
ity each involves the loss of the infected individual’s lifetime
productivity. Based on average months of survival in a study
by the Multi-Society Task Force on PVS,46 we assume that an
individual who enters a PVS stays in that state for four years and
dies thereafter. According to van de Beek et al. (2004),44 severe
disability involves such disability for the rest of the individual’s
expected lifetime. Based on definitions of Glasgow Outcome
Scale outcomes as reported in van de Beek et al. (2004),44 we
assume that both PVS and severe disability necessitate long-term
care – which we take to comprise nursing, domestic, and infor-
mal care – for the duration of disability.47 Nursing care is valued
at the average pre-tax wage in the professional occupations
(“professional wage”), which includes health work; domestic
care is valued at the unskilled wage; and, because we assume
that all potential informal caregivers are equally willing and able
to miss work to provide care, informal care is valued at the
average wage across all adults (see the Methodological
Appendix for details).48
Based on a study by Weisfelt et al. (2006),49 we assume that
moderate disability persists for two years (see the Methodological
Appendix for details). After a study by Schmand et al. (2010),50 we
assume that subsequent good recovery is lifelong. Based on defini-
tions of Glasgow Outcome Scale outcomes as reported in van de
Beek et al. (2004),44 we associate the two years of disability with an
inability to do paid or unpaid work. However, these definitions
also indicate that, unlike PVS and severe disability, moderate
disability does not necessitate long-term care.
Temporary disability includes periods of no productivity
(i.e., absenteeism) and reduced productivity upon returning to
work (i.e., presenteeism), both of which we value at the
average wage. Temporary disability also includes informal
caregivers’ foregone paid work, which we value at the average
wage across all adults.
We derive or construct earnings, employment, and general
mortality risk data from Eurostat (see Table 1 for specific
Eurostat sources by category); 2016 time use data from the
Turkish Statistical Institute (TurkStat);53 duration of absenteeism,
presenteeism, and days of caregiving required during temporary
disability from Wyrwich et al. (2015)54 and Jiang et al. (2012)55
(see the Methodological Appendix for more information regard-
ing how we construct these values); and population age structures
from the World Population Prospects 2015.56 The lack of age-
disaggregation of time use among the elderly in the data leads us
to assume that time use is invariant across all ages 55 and older.
This is implausible since rising disability with age should reduce
work hours among the elderly, but it clearly does not bias our
results. The reason is that we assign the average time use to each
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individual age, therefore we overstate the productivity of the old-
est in the 55 and older age group, but understate that of the
youngest in that age group by an exactly compensating amount.
2.11. Comorbid subpopulation-specific parameters
Our comorbid subpopulation consists of adults who enter the
model aged 18–64 with at least one of the following comor-
bidities: chronic obstructive pulmonary disease, asthma, dia-
betes, chronic kidney failure, chronic heart disease, and
cancer. Prevalence rates of comorbidities come from Turkish
data sources.57–62 We construct parameters for the comorbid
subpopulation by scaling parameter values that apply to
Turkey’s general population to account for the impact of
comorbidities on those parameter values. This involves scaling
up non-PD-related mortality rates, incidence rates, and para-
meters related to length of hospital stay for inpatient and
outpatient CAP (specifically, days before full productivity is
reached for temporary disability, the hours per month of
long-term care, and days of short-term care needed). It
involves scaling down earnings among all comorbid adults,
and vaccine efficacy among those at high risk for pneumo-
coccal disease. The scale factor applied to a particular para-
meter value depends on non-Turkish data on the ratio of that
parameter value in comorbid adults to its value in the general
population. Note that CFRs discussed in Section 2.8 do not
require rescaling since these already apply to comorbid popu-
lations along with the elderly.
See the Methodological Appendix for further detail and
data.
2.12. Vaccination benefits and rate of return
Vaccination benefits equal the indirect costs averted by vacci-
nation, that is, the difference between a vaccinated and unvac-
cinated cohort in the expected present discounted value of
indirect costs of PD. These benefits represent a productivity-
based breakeven level for vaccine costs: any costs in excess of
these benefits would result in a negative productivity-based
rate of return (RoR). These benefits reflect age- and comor-
bidity-status-specific benefits averaged using age- and comor-
bidity-status-specific population weights. We construct these
weights using population data from the World Population
Prospects 201556 and comorbidity prevalence data discussed
in Section 2.10 (see also the Methodological Appendix).
The RoR is the ratio of vaccination benefits to vaccine
procurement and administration costs, minus 1, multiplied
by 100. Since such costs are not in the public domain, we
present hypothetical RoRs over a range of hypothetical costs.
2.13. Discounting and economic growth
We discount costs and benefits at a rate of 3% annually, which is
typical in the economic evaluation literature, and has been
recommended by the Second Panel2 and used in a prior evalua-
tion of PPV23 Adult in Turkey by Akin et al. (2011).16 Note that
all vaccination occurs in the base period (there is a one-time
vaccination opportunity), so their costs do not require discount-
ing. Based on average economic growth rates over 20 years in
Turkey and nine comparator countries, we assume that its
economy, and therefore wages, will grow 2.61% annually. Since
benefits are multiplicative in wages, (see the Methodological
Appendix for benefit formulas), a benefit discount rate of 3%
and a wage growth rate of 2.61% implies an effective discount
rate of 0.39%.
2.14. Currency conversion
To convert monetary input parameters – which are in 2014
euros – to 2017 United States (U.S.) dollars, we first convert
2014 euros to 2017 euros using the ratio of Turkey’s 2017
GDP deflator to its 2014 value, which equals 1.29.63 We then
convert these 2017 euros to 2017 U.S. dollars using the aver-
age monthly exchange rate from January to December 2017
from the U.S. Federal Reserve Economic Data, which equals
1.13.64 Therefore, the final conversion factor by which we
multiply 2014 euro values to yield 2017 U.S. dollar values is
1.29 × 1.13 = 1.46.
2.15. Scenario and sensitivity analyses
Our base case vaccine efficacies (see Section 2.7) allow baseline
vaccine efficacy to decline with age to account for immunose-
nescence among those aged 50 and up. However, given the
prominence of the CAPITA results of vaccine efficacy of 45.0%
for inpatient and outpatient CAP and 75.0% for bacteremia and
meningitis, we perform a scenario analysis using these headline
numbers as baseline vaccine efficacies for all ages within the
program population. We call this our “age-invariant vaccine
efficacy scenario.”
We also assess the sensitivity of vaccine benefits to the
magnitude of herd effects from PCV13 Pediatric by raising
the assumed incidence rate ratio (i.e., the ratio of incidence
rates after herd effects to those before herd effects) from our
baseline value of 0.12 up to 1.00 (i.e., an assumption of no
herd effects) using intervals of 0.04 (i.e., using incidence rate
ratios of 0.12, 0.16, 0.20,…, 0.96, and 1.00). We do so for both
the base case and the age-invariant baseline vaccine efficacy
scenarios.
In our last sensitivity analysis, we derive vaccine-type inci-
dence rates using two alternative estimates of PCV13 vaccine-
type coverage rates, both of which we obtain from Ceyhan
et al. (2016).65 The first alternative coverage rate is 56.6%
based on the Ceyhan et al. estimate for Hungary, and
the second is 85.5% based on the study’s estimate for Turkey.
3. Results
Our results involve two parts: (i) the indirect costs per treat-
ment episode of PD; and (ii) vaccination benefits and RoR.
3.1. Indirect costs
Table 2 presents indirect costs per treatment episode of PD
for the elderly and comorbid subpopulations separately, aver-
aged across ages within each subpopulation using weights
proportional to incidence rates and population size.
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The average indirect costs of each manifestation are higher in
the comorbid subpopulation than in the elderly subpopulation.
The costs are about 5.26 times higher for inpatient CAP, 1.30
times higher for outpatient CAP, 2.50 times higher for bacter-
emia, and nearly twice as high formeningitis.With the exception
of outpatient CAP, the average indirect costs per treatment
episode of each manifestation either exceed or are a substantial
fraction of Turkey’s 2017 per capita GDP of $10,602.17.66 To
help assess these magnitudes’ plausibility, we note that these
indirect costs are not limited to those foregone during or because
of treatment (such as earnings lost from inpatient stays). They
include broader indirect costs like those from premature mor-
tality associated with the episode.
In terms of Figure 1, these manifestation-specific indirect costs
per treatment episode constitute the expected cycle utilities con-
ditional on contracting inpatient CAP, outpatient CAP, bacter-
emia, and meningitis, respectively, after node B. Figure 1 shows
that for eachmanifestation (e.g., inpatient CAP), indirect costs are
the weighted average across the outcomes under that manifesta-
tion (e.g., death and temporary disability in the case of inpatient
CAP) of the outcome-specific indirect costs (e.g., the indirect costs
of death from inpatient CAP and of temporary disability from
inpatient CAP), where the weights equal the probabilities of the
outcomes conditional on infection (e.g., the probability of death
from inpatient CAP infection equals the CFR and the probability
of temporary disability from inpatient CAP is 1 minus the CFR).
Table 3 disaggregates manifestation-specific indirect costs into the
probabilities and indirect costs of the various outcomes possible
under each manifestation. It shows these separately for the elderly
and comorbid subpopulations.
Table 3 shows that death and long-term meningitis seque-
lae are generally at least two orders of magnitude more costly
than temporary disability.
The indirect costs of death at a given age are the same across
all manifestations since the magnitude of the productivity loss
from death does not depend on the cause of death. Table 4
disaggregates the indirect costs of death at sample ages by the
source of productivity losses.
Table 4 shows that the indirect costs of death (and, as a result,
the indirect costs per treatment episode for manifestations other
thanoutpatientCAP) declinewith age. It shows that for ages below
70 years, the largest productivity losses from death come from lost
paid work, then from lost housework, then from either lost car-
egiving or volunteering. Although we value unpaid work less per
unit of time than paid work, the burdens of lost unpaid work
exceed those of lost paid work at ages 70 and older. This is because,
on average, older adults devotemuchmore of their time to unpaid
work than to paid work (a 70-year-old, for example, can look
forward to very little future paid work, but up to 16 more years
of unpaid work).
Table 2. Average indirect costs per treatment episode (2017 USD) and percent









Average indirect costs $4,449.42 $23,385.72
Percent of 2017 per capita GDP 42.0% 220.6%
Outpatient CAP
Average indirect costs $250.12 $325.87
Percent of 2017 per capita GDP 2.4% 3.1%
Bacteremia
Average indirect costs $12,724.00 $31,865.32
Percent of 2017 per capita GDP 120.0% 300.6%
Meningitis
Average indirect costs $17,219.52 $34,392.25
Percent of 2017 per capita GDP 162.4% 324.4%
Table 3. Average indirect costs per treatment episode (2017 USD) by PD manifestation, disease outcome and subpopulation.
Death TD PVS SD MD
Prob. IC Prob. IC Prob. IC Prob. IC Prob. IC
Inpatient CAP
Elderly 0.09 $44,707.71 0.91 $370.39 - - - - - -
Comorbid 0.09 $248,957.16 0.91 $530.46 - - - - - -
Outpatient CAP
Elderly - - 1.00 $250.12 - - - - - -
Comorbid - - 1.00 $325.87 - - - - - -
Bacteremia
Elderly 0.29 $42,651.37 0.71 $446.06 - - - - - -
Comorbid 0.22 $198,973.50 0.78 $556.03 - - - - - -
Meningitis
Elderly 0.29 $42,651.37 0.51 $446.06 0.01 $46,856.68 0.05 $51,093.16 0.14 $10,728.54
Comorbid 0.11 $242,031.82 0.69 $589.10 0.01 $246,759.71 0.05 $268,885.70 0.14 $16,604.79
Abbreviations: CAP = community-acquired pneumonia; Prob. = probability; IC = indirect costs; TD = temporary disability; PVS = persistent vegetative state; SD =
severe disability; MD = moderate disability.





















20 $406,916.87 $247,306.57 $113,891.41 $23,745.30 $21,973.59
25 $390,629.81 $236,416.70 $109,515.35 $22,832.93 $21,864.84
30 $361,079.55 $219,869.95 $99,042.01 $20,649.34 $21,518.26
35 $317,163.42 $190,346.45 $87,466.06 $18,235.86 $21,115.05
40 $272,491.98 $160,026.76 $76,200.24 $15,887.04 $20,377.93
45 $223,802.39 $126,119.12 $64,609.60 $13,470.50 $19,603.17
50 $178,421.36 $95,069.74 $54,080.23 $11,275.22 $17,996.16
55 $140,278.93 $70,477.34 $44,020.45 $9,177.85 $16,603.29
60 $109,777.97 $52,714.98 $35,986.83 $7,502.92 $13,573.23
65 $76,178.98 $30,694.15 $28,685.05 $5,980.57 $10,819.21
70 $50,546.39 $15,630.26 $22,019.90 $4,590.94 $8,305.30
75 $31,319.77 $6,431.84 $15,695.60 $3,272.39 $5,919.94
80 $19,634.50 $4,032.15 $9,839.64 $2,051.47 $3,711.24
85 $2,181.91 $448.08 $1,093.44 $227.97 $412.42
Elderly subpopulation
65 $89,776.42 $37,640.02 $32,879.87 $6,855.15 $12,401.38
70 $58,548.12 $19,167.55 $24,835.40 $5,177.95 $9,367.22
75 $35,287.01 $7,947.16 $17,241.91 $3,594.78 $6,503.17
80 $19,892.18 $4,480.01 $9,719.70 $2,026.47 $3,666.00
85 $2,237.82 $503.99 $1,093.44 $227.97 $412.42
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The indirect costs per treatment episode of inpatient CAP
in Table 2 are much lower than those of bacteremia and
meningitis (recall that these indirect costs are weighted
averages of the indirect costs of death and disability associated
with that episode). However, as Table 1 shows, the incidence
of inpatient CAP is much higher than that of either bacter-
emia or meningitis. Thus, the expected indirect costs of inpa-
tient CAP (i.e., the indirect costs of a treatment episode
multiplied by the probability of such episode, where the
probability equals the incidence rate) are much higher than
those of either bacteremia or meningitis. Across the comorbid
and elderly populations, the expected indirect costs of
a treatment episode are €2,232.88 for inpatient CAP, €3.73
for bacteremia, and €0.92 for meningitis. Thus, the expected
indirect costs associated with inpatient CAP are over two
orders of magnitude larger than those associated with either
bacteremia or meningitis. Indeed, the expected indirect costs
of outpatient CAP across the comorbid and elderly popula-
tions are €119.63, which is over an order of magnitude larger
than those of bacteremia and meningitis.
3.2. Vaccination benefits and rate of return
Vaccination benefits can be differentiated by age and comorbid-
ity status. The solid curve with the downward trajectory in
Figure 2 shows these vaccine benefits in our base case vaccine
efficacy scenario. The vertical line in Figure 2 separates the
vaccine benefits curve into two segments: the left of the line
represents vaccination benefits in the comorbid subpopulation,
and the right of the line represents vaccination benefits in the
elderly subpopulation.
These per-person vaccination benefits are $550 for comorbid
adults aged 18 at vaccination and decline to a little above $50 for
comorbid adults aged 64. These benefits are $35 for elderly aged
65 and decline to nearly zero at higher ages. Among the mani-
festations and outcomes, the averted indirect costs of death from
inpatient CAP account for the largest share of these vaccine
benefits because of: (i) inpatient CAP’s much higher incidence
rates relative to those of either bacteremia or meningitis; and (ii)
the very high indirect costs of death relative to the indirect costs
of temporary disability. Vaccination benefits fall with age due to
declining lifetime potential productivity. In the elderly subpo-
pulation, benefits decline in later years largely because of our
model’s termination after age 85, which given a maximum of 15
years of vaccine efficacy, truncates the benefit stream of those
vaccinated after age 71.
The comorbid subpopulation receives considerably greater
vaccine benefits than the elderly subpopulation largely
because the former has higher indirect costs per inpatient
CAP treatment episode. This stems from comorbid adults
being younger and therefore having longer productive life-
spans to protect with vaccination.
Averaging vaccination benefits across the entire program
population yields a program-wide per-person vaccination
benefit of $207.02. This program-wide per-person benefit
mainly reflects the benefits from vaccinating the younger
comorbid subpopulation rather than the elderly subpopula-
tion because the former group is almost four times the size of
the latter in the Turkish population.
Since vaccination costs in Turkey are not in the public
domain, we present hypothetical rates of return (RoRs) for
a range of vaccination costs between $10 and $150 in Figure 3.
Figure 2. Benefits of PCV13 Adult by age at vaccination, assuming herd effects from pediatric vaccination. The solid curve shows vaccine benefits in our base case
scenario, which assumes age-varying baseline vaccine efficacies. The dashed curve shows vaccine benefits in our scenario analysis that replaces our base case vaccine
efficacies with age-invariant baseline vaccine efficacies.
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The relation between hypothetical vaccination cost (on the hor-
izontal axis) and hypothetical RoR (on the vertical axis) for our
base case vaccine efficacy scenario is shown in the solid curve.
Breakeven vaccination costs – that is, vaccination costs yield-
ing an RoR of zero – by definition equal the program-wide
vaccination benefits of $207.02. The hypothetical RoR is positive
at hypothetical vaccination costs below this breakeven level and
negative at hypothetical costs above it. At hypothetical vaccina-
tion costs of $10, the RoR would be nearly 2,000%. At vaccina-
tion costs of: $20, the RoR would be slightly over 900%; $50, the
RoR would be slightly over 300%; $80, the RoR would be nearly
160%; $100, the RoR would be slightly over 100%; and $150, the
RoR would be 38%.
3.3. Scenario and sensitivity analyses
Our first scenario analysis replaces our baseline vaccine efficacies
with age-invariant baseline vaccine efficacies. This results in the
dashed and downward sloping age-varying vaccine benefit curve
in Figure 2, and the dashed curve linking hypothetical vaccination
costs and RoRs in Figure 3. Vaccination benefits averaged across
the program cohort under this age-invariant vaccine efficacy sce-
nario are $120.41.
The most important effect of this scenario analysis is to reduce
vaccination benefits and RoRs. This is because the age-invariant
baseline vaccine efficacies in this scenario come from the CAPITA
trial whose sample consists of elderly aged 65 and up.
Extrapolating baseline vaccine efficacy from this age group to all
younger ages therefore involves extrapolating the immunosenes-
cence within this age group to the entire and often much younger
program subpopulation. In contrast, our base case vaccine efficacy
scenario allows vaccine efficacy to be higher in the non-elderly
than in the elderly, reflecting the reduced role of immunosenes-
cence in the former.
Computing program-wide vaccination benefits for intermedi-
ate incidence rate ratios for herd effects from PCV13 Pediatric
between 0.12 (which we use for our base case analysis) and 1.00
(which implies no herd effects) yields the results in Figure 4.
Figure 4 shows that program-wide per person vaccination
benefits rise quickly with weakening herd effects. For exam-
ple, assuming no herd effects, average benefits are approxi-
mately 5.8 times greater ($1,199/$207). This suggests that if
herd effects were weaker than our base case assumes, then the
benefits of vaccinating adults would quickly become massive.
Figure 4 also shows a substantial difference in average
vaccination benefits between our base case and age-invariant
vaccine efficacy scenarios. As discussed above with respect to
the results illustrated in Figures 2 and 3, this result is
explained by the considerably higher baseline vaccine efficacy
rates used in the base case compared to those used in the age-
invariant efficacy scenario for ages 18–64.
Deriving vaccine-type incidence rates using PCV13 cover-
age of 56.6% (Hungary-specific estimates) and 85.5% (Turkey-
specific estimates) yields program-wide vaccination benefits of
$172.33 and $260.26, respectively.
4. Discussion
In contrast to much of the economic evaluation literature on
PCV13 Adult, we use a (limited) societal perspective CBA using
Figure 3. Rate of return to the entire Turkish PCV13 Adult program by vaccination cost, assuming herd effects from pediatric vaccination. The solid curve shows rates
of return in our base case scenario, which assumes age-varying baseline vaccine efficacies. The dashed curve shows rates of return in our scenario analysis that
replaces our base case vaccine efficacies with age-invariant baseline vaccine efficacies.
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a human capital approach and incorporating unpaidwork. And in
contrast to that literature, we find large vaccination benefits even
in the presence of PPV23 and herd effects from PCV13 pediatric.
The broadening of perspective from a health payer’s perspective to
a societal perspective raises the benefits of vaccination by $207.02.
Our more specific empirical conclusions are as follows. First, PD’s
indirect costs in Turkey are large relative to benchmarks like
Turkish per capita GDP. Economic theory and welfare economics
affirm the value of unpaid work and our indirect costs results
prove their quantitative importance in assessing disease burdens
and valuing the health of older adults and the elderly. Second, the
indirect costs per treatment episode of PD are largely accounted
for by the costs of death rather than the costs of temporary
disability, by the costs of inpatient CAP rather than the costs of
other manifestations, and by the value of market productivity
rather than nonmarket productivity among those younger than
age 70. Third, vaccination benefits are larger in the younger
comorbid subpopulation than in the elderly subpopulation
because of the longer productive lifespans that can be protected
with vaccination. Fourth, the productivity-based RoR to Turkey’s
PCV13 Adult program is sizeable for a wide range of hypothetical
vaccination costs. For example, Turkey-specific estimates of the
return to investments in schooling are below 20%.67 Estimates of
the return to theGlobal Alliance for Vaccines and Immunization’s
immunization program are between 12–18%,68 and the return to
the Expanded Programme on Immunization vaccination in the
Philippines is estimated at 21%.69 In contrast, at a hypothetical
vaccination cost of $50, the RoR to PCV13 Adult in the program
population is approximately 300%.
We emphasize that these benefit and RoR calculations
reflect productivity benefits alone. They exclude other
elements of value, most importantly the intrinsic value of
health itself, but also averted direct costs and other socio-
economic benefits such as the effects on leisure.
4.1. Policy implications
The fundamental principle animating our analysis is that policy-
makers should evaluate vaccines in light of their full socio-
economic benefits over and above narrow QALY gains and
avoided medical care costs. Failing to account for vaccines’ full
value – including their full productivity value – risks substantial
undervaluation. The RoRs we found at a range of hypothetical
vaccination costs imply that on productivity grounds alone
PCV13 Adult is likely to be a sufficiently attractive investment
relative to other publicly-financed health and non-health
expenditures.
Another policy implication is the considerable benefit to
vaccinating non-elderly comorbid adults, a result of their high
prospective lifetime productivity and substantial reductions in
mortality risk from vaccination.
4.2. Limitations
Our analysis omits health, direct costs, consumption, leisure,
financial risk protection, social equity, complete fiscal and
macroeconomic impacts, and other broad benefits resulting
from PCV13 Adult vaccination, consideration of which we
expect to raise the RoR. On the other hand, we also omit
consideration of aging-related health care and social care,
which would lower the RoR. Given the current state of the
literature, it is not clear whether the omitted positive factors
Figure 4. Average vaccination benefits by incidence rate ratio over the entire Turkish PCV13 Adult program. The solid curve shows vaccine benefits in our base case
scenario, which assumes age-varying baseline vaccine efficacies. The dashed curve shows vaccine benefits in our scenario analysis that replaces our base case vaccine
efficacies with age-invariant baseline vaccine efficacies.
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dominate the omitted negative ones or vice versa. But this
suggests that our RoRs do not obviously overstate or under-
state those that would result from a full societal perspective,
and so are at least somewhat informative of such results.
Data are limited in Turkey, compelling the use of many
assumptions and imputations. Real-world data on long-term
vaccine effectiveness, herd effects from PCV13 Pediatric (the
magnitude of which, in turn, depends on carriage prevalence in
children and adults and the impact of pediatric vaccination on
such carriage),70,71 and possible herd or serotype replacement
effects from adult vaccination are incomplete. Estimates of inpa-
tient CAP and IPD incidence depend on hospital discharge
records, which suffer from underreporting,72–74 though this
makes our estimates conservative. Data scarcity compelled us to
calibrate our calculations with data from other countries (e.g., the
United States with respect to the productivity losses associated
with temporary disability54). Whether these data limitations com-
bine to produce more or less conservative estimates is unclear.
4.3. Implications for future work
Our analysis improves on the existing empirical literature by
measuring the indirect costs of adult PD and the productivity-
based social RoR to PCV13 Adult, which integrates death and
disability over a lifetime, invasive and noninvasive PD, and paid
and unpaid work. We argue that such analysis is firmly grounded
in CBA from a societal perspective and defend against ethical
concerns.
There are some obvious directions for future work. The first
is to expand our empirical analysis and theoretical framework to
encompass leisure in addition to productivity. Such an analysis
would show how producible goods and services and leisure
jointly determine well-being and would also allow us to quantify
in monetary terms the contribution that PCV13 Adult can make
toward the European Commission’s75 and World Health
Organization’s76 policy goal of promoting Healthy Aging.
The second direction for future work is to investigate more
fully the relationship between PD and chronic disease comorbid-
ities. Our analysis of Danish diabetics and Turkish comorbid
adults suggests that the benefits of vaccinating adults and elderly
with chronic disease against PD may be especially high.77 In the
language of economic theory, this may be because chronic disease
status is a conveniently observable marker for targeting PCV13 to
adults for whom vaccination has especially high benefits.
Expanding this work to consider more explicitly the interactions
among PD, other chronic and infectious diseases, long-term and
permanent disability, and early retirement from the workforce
may be valuable.
A third direction for future work could be to move beyond
a consideration of PD and PCV13 adult in isolation, toward
evaluating its role within a life course vaccination framework.
Such a framework would simultaneously consider all vaccine-
preventable diseases and their associated comorbidities and vac-
cines and attempt to design a lifetime vaccine schedule that is
optimal in the sense of maximizing some social objective like
QALYs per euro spent or (better, in our judgment) the social
rate of return.
Finally, a fourth direction could be to evaluate PCV13
Adult’s contribution to reducing the risks of antimicrobial
resistance (AMR). Some forms of Streptococcus pneumoniae
have become resistant to antibiotics, and PCV13 protects
against some of these forms (e.g., serotype 19A).78 Such
analysis could be especially valuable given the prominence
of AMR among global health priorities and the dearth of
empirical estimates of the value of vaccines in prevent-
ing AMR.
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